STOK Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of 71.19% compared to Stoke Therapeutics's net margin of -49.65%. Stoke Therapeutics's return on equity of 21.05% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Stoke Therapeutics has a consensus price target of $22.38, signalling upside risk potential of 93.72%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 35.98%. Given that Stoke Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Stoke Therapeutics is more attractive than NovaBay Pharmaceuticals.

Stoke Therapeutics has a beta of 1.141, which suggesting that the stock is 14.074% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $158.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Stoke Therapeutics's net income of $112.9M is higher than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Stoke Therapeutics's price-to-earnings ratio is 14.62x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 3.46x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nanoviricides has a net margin of 71.19% compared to Stoke Therapeutics's net margin of --. Stoke Therapeutics's return on equity of 21.05% beat Nanoviricides's return on equity of --.

Stoke Therapeutics has a consensus price target of $22.38, signalling upside risk potential of 93.72%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 367.63%. Given that Nanoviricides has higher upside potential than Stoke Therapeutics, analysts believe Nanoviricides is more attractive than Stoke Therapeutics.

Stoke Therapeutics has a beta of 1.141, which suggesting that the stock is 14.074% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $158.6M, which are larger than Nanoviricides quarterly revenues of --. Stoke Therapeutics's net income of $112.9M is higher than Nanoviricides's net income of -$2.2M. Notably, Stoke Therapeutics's price-to-earnings ratio is 14.62x while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 3.46x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of 71.19% compared to Stoke Therapeutics's net margin of --. Stoke Therapeutics's return on equity of 21.05% beat Oragenics's return on equity of --.

Stoke Therapeutics has a consensus price target of $22.38, signalling upside risk potential of 93.72%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1983.54%. Given that Oragenics has higher upside potential than Stoke Therapeutics, analysts believe Oragenics is more attractive than Stoke Therapeutics.

Stoke Therapeutics has a beta of 1.141, which suggesting that the stock is 14.074% more volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $158.6M, which are larger than Oragenics quarterly revenues of --. Stoke Therapeutics's net income of $112.9M is higher than Oragenics's net income of -$2.2M. Notably, Stoke Therapeutics's price-to-earnings ratio is 14.62x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 3.46x versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 71.19% compared to Stoke Therapeutics's net margin of --. Stoke Therapeutics's return on equity of 21.05% beat Theriva Biologics's return on equity of --.

Stoke Therapeutics has a consensus price target of $22.38, signalling upside risk potential of 93.72%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1455.56%. Given that Theriva Biologics has higher upside potential than Stoke Therapeutics, analysts believe Theriva Biologics is more attractive than Stoke Therapeutics.

Stoke Therapeutics has a beta of 1.141, which suggesting that the stock is 14.074% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Stoke Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Stoke Therapeutics quarterly revenues are $158.6M, which are larger than Theriva Biologics quarterly revenues of --. Stoke Therapeutics's net income of $112.9M is higher than Theriva Biologics's net income of -$4.3M. Notably, Stoke Therapeutics's price-to-earnings ratio is 14.62x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics is 3.46x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.